Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000725059 | SCV000333636 | likely pathogenic | not provided | 2015-08-11 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000316051 | SCV001572441 | likely pathogenic | Smith-Lemli-Opitz syndrome | 2021-04-01 | criteria provided, single submitter | clinical testing | Variant summary: DHCR7 c.1348delC (p.Arg450AlafsX31) located in the last exon (exon 9) causes a frameshift which results in an extension of the protein. The variant was absent in 248600 control chromosomes. c.1348delC has been reported in the literature in one heterozygous individual who had a near normal ratio of fractional choloesterol synthesis (Wassif_2005). These report(s) do not provide unequivocal conclusions about association of the variant with Smith-Lemli-Opitz Syndrome. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. One laboratory classified the variant as likely pathogenic, and one laboratory classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as likely pathogenic. |
Labcorp Genetics |
RCV000316051 | SCV001576443 | pathogenic | Smith-Lemli-Opitz syndrome | 2023-12-15 | criteria provided, single submitter | clinical testing | This sequence change results in a frameshift in the DHCR7 gene (p.Arg450Alafs*31). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 26 amino acid(s) of the DHCR7 protein and extend the protein by 4 additional amino acid residues. This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with DHCR7-related conditions. ClinVar contains an entry for this variant (Variation ID: 282268). This variant disrupts a region of the DHCR7 protein in which other variant(s) (p.Arg450Leu) have been determined to be pathogenic (PMID: 10405455, 15896653, 16181459, 22391996, 25405082). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
Gene |
RCV000725059 | SCV001784580 | likely pathogenic | not provided | 2023-11-01 | criteria provided, single submitter | clinical testing | Frameshift variant in the C-terminus predicted to result in protein truncation, as the last 26 amino acids are lost and replaced with 30 incorrect amino acids; Not observed in large population cohorts (gnomAD); Has not been previously published as pathogenic or benign to our knowledge |
Fulgent Genetics, |
RCV000316051 | SCV002813917 | likely pathogenic | Smith-Lemli-Opitz syndrome | 2022-02-10 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000316051 | SCV000800696 | uncertain significance | Smith-Lemli-Opitz syndrome | 2018-04-20 | no assertion criteria provided | clinical testing | |
Natera, |
RCV000316051 | SCV002092993 | likely pathogenic | Smith-Lemli-Opitz syndrome | 2019-12-23 | no assertion criteria provided | clinical testing |